He tried 3 injection sites on Mounjaro. Only 1 worked.

Dr. Kevin Joseph switched from his abdomen to his thigh for one week at 1.25 mg and his appetite suppression vanished. The Lilly study tells you why.

Where to inject for MAXIMUM GLP-1 Weight Loss | Breaking down the data

Kevin Joseph had been on 1.25 mg of tirzepatide for months. The dose was starting to wear off by day four or five, his appetite was creeping back, and he had two choices: bump the dose to 2.5 mg or shorten the interval to every five days.

Then he saw a post on Reddit. Someone said switching from the abdomen to the thigh brought back their appetite suppression and helped them lose more weight. He had nothing to lose. So he loaded his pen, pinned his upper thigh instead of his stomach, and spent the next seven days counting down until he could inject again.

Zero appetite suppression. No constipation either, which had been his main side effect, but also no satiety, no food noise reduction, nothing. "I don't even know what's going on," he says. "It's not giving me positives, it's not giving me negatives." The following week he went back to his abdomen and everything returned.

I had zero appetite suppression that week. Even though the 1.25 was wearing off, this was like nothing.Dr. Kevin Joseph, DO

1. The Lilly study used 54 people and three injection sites

Eli Lilly ran a small trial with 54 participants, breaking them into three groups of 18. Each person got a single 5 mg dose of tirzepatide in three different sites over three phases: abdomen, upper arm and thigh. Between each injection there was a 35 day washout period, long enough for the drug to clear completely. Tirzepatide has a five day half life, so four half lives equals 20 days for total elimination. Lilly waited 35 to be safe.

The researchers measured how much drug entered the bloodstream from pre dose to 480 hours after injection, roughly 20 days. They also tracked maximum concentration in the blood and side effects reported at each site.

Why this matters if you haven’t started yet: If you are new to GLP-1s, those three sites, abdomen, upper arm and thigh, are the three FDA approved injection locations listed in the pamphlet that comes with Ozempic, Wegovy, Mounjaro and Zepbound.

2. The abdomen absorbed 24% of the drug. The thigh absorbed 22%.

Between zero and 480 hours, the abdomen allowed 24% of the injected dose to enter the bloodstream. The upper arm absorbed 21%. The thigh absorbed 22%.

That means the abdomen gave the fastest uptake, but only by about 2 to 3 percentage points. The study did not calculate whether that difference was statistically or clinically significant, and Joseph flags that as a problem. With only 54 people in the trial, he says, it is hard to know if the raw numbers matter in the real world.

3. The abdomen also gave the highest maximum concentration

The researchers measured peak drug concentration at the same time intervals. The abdomen hit 25% maximum concentration. The upper arm reached 23%. The thigh reached 21%.

Again, the abdomen won, but only by about 4 percentage points at most. Joseph is blunt about the limits of the data. The sample size was very small compared to the tirzepatide obesity trials, which enrolled a few thousand participants. He says the findings are interesting but not mind blowing.

4. The abdomen caused more nausea and more appetite suppression

The study also tracked adverse events. Abdominal injections caused more nausea and vomiting than upper arm or thigh injections.

But 24% of participants reported decreased appetite with abdominal injections, compared to only 13% with the upper arm and 5% with the thigh. That is a 19 to 20 percentage point difference in subjective appetite suppression, much larger than the pharmacokinetic differences.

The tradeoff: more appetite suppression, more side effects. Less appetite suppression, fewer side effects.

Why this matters if you haven’t started yet: If you are dealing with debilitating nausea, vomiting or constipation, Joseph recommends trying a different injection site before you stop the drug or drop your dose.

5. He stayed at 1.25 mg and switched sites instead of increasing his dose

Joseph had been micro dosing tirzepatide, taking 1.25 mg instead of the standard 2.5 mg starting dose. When his appetite suppression started to fade around day four or five, he considered two options: increase to 2.5 mg or shorten the interval to every five days, which lines up with the drug's half life.

Instead he tried the thigh, based on that Reddit post. It was a disaster. He had no appetite suppression all week. His biggest side effect, constipation, disappeared, but so did everything good about the drug. The hunger and food noise he had been managing on 1.25 mg came roaring back.

The next week he returned to his abdomen. Appetite suppression returned. Constipation returned. He could tell the drug was working again.

6. He ended up dosing every five days instead of every seven

Joseph eventually moved from 1.25 mg every seven days to 1.25 mg every five days. He says he feels great on that schedule and the constipation has mostly resolved after a year and a half on the drug.

If he wants to restart weight loss, he might go up to 2.5 mg. For now, the shorter interval at the lower dose is working.

My body after being on it for almost a year and a half kind of got used to it.Dr. Kevin Joseph, DO

7. You do not need to rotate sites unless you have a reason

Joseph says there is a worry online that staying in the same injection site will cause some kind of desensitization. It will not. The skin and fat are just a vehicle to carry the medication into your bloodstream. You can inject in the same location for the rest of your life and it will not make a difference.

But if your current site is not working, if you are not getting appetite suppression or if your side effects are landing you in the emergency department, try rotating. See what happens. Once you find the site that works, the one that keeps food noise down and side effects tolerable, stick with it.

There is no study showing that rotating improves weight loss. Once you find your sweet spot, stay there.

Once you find an injection site that allows for you to lose weight and keeps food noise at bay, just stick to it.Dr. Kevin Joseph, DO

If your goal is weight loss, Joseph recommends starting with the abdomen. That is where the raw data and his own experience, plus most of his patients, have been most successful. Then weigh appetite suppression against side effects. If the nausea or vomiting or constipation becomes debilitating, move to the arm or thigh and see if it makes a difference.

The study had 54 people and a few percentage points of separation. Your body has one injection site that works. Find it, then stop moving.

Questions people ask

Does it matter where I inject Mounjaro or Ozempic for weight loss?

A small Lilly study found the abdomen absorbed tirzepatide slightly faster and gave higher maximum concentration than the thigh or upper arm, by 2 to 4 percentage points. It also caused more appetite suppression but more nausea. The differences were small and the study was not powered to show clinical significance.

Do I need to rotate injection sites on a GLP-1?

No. There is no evidence that staying in one site causes desensitization or reduces effectiveness. Rotate only if your current site is giving you unbearable side effects or not controlling your appetite. Once you find a site that works, stick with it.

Which injection site has the fewest side effects on tirzepatide?

In the Lilly study, the thigh and upper arm caused less nausea and vomiting than the abdomen. Dr. Joseph had zero constipation when he injected his thigh, but also zero appetite suppression. The tradeoff is individual.

DK
Dr. Kevin Joseph, DO

Dr. Kevin Joseph is an internal medicine physician in upstate New York who lost over 140 lb using GLP-1 therapy and now treats patients with tirzepatide and semaglutide. 1,556,659 views on the original video.

Watch the original on YouTube →

Trending Topics